KRAS G12C inhibitors have shown promise in KRAS G12C-mutant lung cancer but intrinsic and acquired resistance are common. Cotreatment with inhibitors of the protein phosphatase SHP2 can abrogate the adaptive response of cancer cells to KRAS inhibitors resulting in greater suppression of MAPK signaling and enhanced tumor growth inhibition.See related article by Ryan et al., p. xxx.

中文翻译：

---

通过垂直途径靶向克服对KRAS抑制剂的适应性抵抗力。

KRAS G12C抑制剂已在KRAS G12C突变型肺癌中显示出希望，但内源性和获得性耐药是常见的。与蛋白磷酸酶SHP2抑制剂共同处理可消除癌细胞对KRAS抑制剂的适应性反应，从而导致对MAPK信号的更大抑制和增强的肿瘤生长抑制作用。xxx。